Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases-Reference-Cited by-同舟云学术

Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases

Published:2022-02-11 Issue:6 Volume:29 Page:3387-3389
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Khin Nyan Y.^ORCID,De Silva Madhawa,Clarke Stephen,Pavlakis Nick,Rogan Chris M.,Ho-Shon Kevin,Lane Rodney J.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-11348-z.pdf

Reference8 articles.

1. Lane RJ, Khin NY, Rogan CM, Magnussen J, Pavlakis N, Lane DM, et al. Safety and feasibility of repeatable hepatic vascular isolation chemotherapy: a pilot study. Ann Surg Oncol. 2016;23:3699–708.

2. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–19.

3. Andersen SE, Andersen IB, Jensen BV, Pfeiffer P, Ota T, Larsen JS. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. Acta Oncol. 2019;58:1149–57.

4. Novakova-Jiresova A, Kopeckova K, Boublikova L, Chloupkova R, Melichar B, Petruzelka L, et al. Regorafenib for metastatic colorectal cancer: an analysis of a registry-based cohort of 555 patients. Cancer Manag Res. 2020;12:5365–72.

5. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (Lond, Engl). 2013;381:303–12.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An arterial access system for targeted chemotherapy delivery and arterial-arterial extracorporeal recirculation for ‘end stage’ peripheral vascular disease;The Journal of Vascular Access;2023-04-08